Keywords: Human Genome Sciences, GlaxoSmithKline, M&A, Unsolicited bid

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline

Article | 20 April 2012

Print This

US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited proposal from UK pharma giant ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in